At the 6th Annual Scientific Meeting of the Japanese Society of Foot Care and Podiatric Medicine, held from February 27th to 28th , a presentation was given on comprehensive angiogenesis therapy for severe chronic lower limb ischemia (CLTI) using ICS-001, which is currently undergoing clinical trials. As a sponsored seminar co-hosted by our company, under the moderation of Dr. Atsuhiko Kawamoto of the Kobe Biomedical Innovation Cluster (TRI), presentations were given by Dr. O

We have been selected for the "J-StarX Biotech Accelerator Program," an entrepreneurship development program run by JETRO that supports startups aiming to enter the US market in the biopharmaceutical field . Using this program as a springboard, we will accelerate the overseas expansion of angiogenesis therapy using ICS for critical lower limb ischemia. https://www.jetro.go.jp/services/j-starx/Biotech.html https://jetro-gov.note.jp/n/n14f3bfcb1c13

We received a Special Jury Prize at the "Changing Tomorrow" pitch contest, hosted by LINK-J and held on February 12th, as part of the "Innovation Series for the Kashiwanoha-Tsukuba Life Science Cluster." Taking this as an opportunity, we will strongly promote the development of angiogenesis therapy using ICS for severe lower limb ischemia . https://www.link-j.org/news/article-51102.html

We have been selected for the "2025 Second Round Research and Development Grant" by the Mitsubishi UFJ Technology Development Foundation, which targets research and development of new technologies and products conducted by venture companies and other organizations. Taking this as an opportunity, we will promote the development of angiogenesis therapy using ICS for critical lower limb ischemia . https://www.mutech.or.jp/info/2025%e5%b9%b4%e5%ba%a6%e7%ac%ac2%e5%9b%9e%e7%a0%94%e